TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05954312: A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Sponsor: Vividion Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 290 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT05954312 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05954312 Rescue Dossier →